FDA Approves First At-Home Nasal Spray Flu Vaccine

FluMist can now be self-administered by adults and caregivers, enhancing convenience and accessibility.

The FDA has approved FluMist, a nasal spray flu vaccine, for self-administration at home for individuals aged 2 to 49.
FluMist is a live, attenuated vaccine that protects against influenza A and B viruses.
Clinical trials demonstrated that FluMist is as safe and effective when self-administered as when given by healthcare professionals.
The vaccine will be available for home delivery through an online pharmacy by the fall of 2025, requiring a pre-approved prescription.
Certain groups, including pregnant individuals and those with weakened immune systems, should not use FluMist due to its live virus content.